famotidine has been researched along with Hyperprolactinemia in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Hyperprolactinemia: Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delpre, G | 1 |
| Lapidot, M | 1 |
| Lipchitz, A | 1 |
| Livni, E | 1 |
| Kadish, U | 1 |
1 other study available for famotidine and Hyperprolactinemia
| Article | Year |
|---|---|
Hyperprolactinaemia during famotidine therapy.
Topics: Aged; Breast; Famotidine; Female; Humans; Hyperprolactinemia | 1993 |